In collaboration with your primary care team, we offer the psychological and psychiatric components that are often missing from most programs that address weight management programs
In the landmark SELECT trial in 2023, the scope of GLP-1RAs was expanded to assess cardiovascular risk in patients with preexisting cardiovascular disease who were overweight or obese without type 2 diabetes [48]
Patients today have more effective weight-loss options than ever before, so this is a logical extension of our work, she said
About Our Compounded Medications Affinity Whole Health provides GLP-1 compounded medications through licensed, highly regulated facilities: Prepared in State Board of Pharmacy licensed compounding pharmacies Or produced in FDA-registered 503(b) Outsourcing Facilities Compounded specifically for each patient, based on a providers prescription Not FDA-approved, due to their individualized nature Formulated to meet unique needs in dose, strength, and delivery Only prescribed after a thorough consultation and medical history review While compounded medications are held to strict quality and safety standards, they may differ in results and risk profile when compared to FDA-approved drugs
An exploratory analysis of genetic data of patients from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial showed that different haplotypes encoding for GLP-1R correlated with variable response rates to antipsychotic medications 132